mitoxantrone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antineoplastics; anthraquinone derivatives	1821	65271-80-9

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: mitoxantrone mitoxantrone hydrochloride dihydroxyanthraquinone mitoxanthrone mitozantrone nimitoxantron mitoxantrone dihydrochloride mitoxantrone HCl	An anthracenedione-derived antineoplastic agent. Molecular weight: 444.49 Formula: C22H28N4O6 CLOGP: 2.24 LIPINSKI: 1 HAC: 10 HDO: 8 TPSA: 163.18 ALOGS: -2.78 ROTB: 12 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

mitoxantrone
mitoxantrone hydrochloride
dihydroxyanthraquinone
mitoxanthrone
mitozantrone
nimitoxantron
mitoxantrone dihydrochloride
mitoxantrone HCl

An anthracenedione-derived antineoplastic agent.

Molecular weight: 444.49
Formula: C22H28N4O6
CLOGP: 2.24
LIPINSKI: 1
HAC: 10
HDO: 8
TPSA: 163.18
ALOGS: -2.78
ROTB: 12

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	7.50 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	7 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.78 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	0 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	12 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	7.90 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.25 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	53 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Dec. 23, 1987	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile neutropenia	304.10	26.17	165	5211	97502	50502246
Acute myeloid leukaemia	207.91	26.17	73	5303	15001	50584747
Myelodysplastic syndrome	159.10	26.17	60	5316	15072	50584676
Pancytopenia	127.51	26.17	90	5286	83940	50515808
Second primary malignancy	116.78	26.17	39	5337	6875	50592873
Sepsis	112.54	26.17	101	5275	132824	50466924
Acute promyelocytic leukaemia	103.66	26.17	23	5353	861	50598887
Neutropenia	103.29	26.17	101	5275	147864	50451884
Thrombocytopenia	83.20	26.17	84	5292	127589	50472159
Leukaemia recurrent	80.40	26.17	20	5356	1234	50598514
Haemophagocytic lymphohistiocytosis	75.63	26.17	30	5346	8603	50591145
Progressive multifocal leukoencephalopathy	70.66	26.17	31	5345	11426	50588322
Bone marrow failure	70.19	26.17	41	5335	27583	50572165
Acute myeloid leukaemia recurrent	68.64	26.17	18	5358	1372	50598376
Bronchopulmonary aspergillosis	65.17	26.17	26	5350	7566	50592182
Febrile bone marrow aplasia	59.03	26.17	23	5353	6288	50593460
Chronic hepatitis	56.89	26.17	14	5362	826	50598922
Congestive cardiomyopathy	51.22	26.17	20	5356	5498	50594250
Lower respiratory tract infection fungal	47.70	26.17	10	5366	285	50599463
Product use in unapproved indication	47.58	26.17	60	5316	115759	50483989
Mucormycosis	45.89	26.17	15	5361	2468	50597280
Cardiac failure	43.99	26.17	47	5329	75993	50523755
Haematotoxicity	41.16	26.17	19	5357	7876	50591872
Acute lymphocytic leukaemia recurrent	40.87	26.17	13	5363	1962	50597786
Streptococcal bacteraemia	40.37	26.17	12	5364	1446	50598302
Abdominal wall wound	40.10	26.17	7	5369	72	50599676
Chloroma	39.05	26.17	8	5368	203	50599545
Graft versus host disease	39.04	26.17	17	5359	6149	50593599
Bone marrow infiltration	37.85	26.17	9	5367	459	50599289
Hypogammaglobulinaemia	37.02	26.17	16	5360	5683	50594065
Myeloblast percentage decreased	36.56	26.17	6	5370	41	50599707
Refractory cytopenia with multilineage dysplasia	35.71	26.17	7	5369	141	50599607
Multiple organ dysfunction syndrome	34.32	26.17	34	5342	50303	50549445
Aspergillus infection	34.26	26.17	16	5360	6805	50592943
Hepatitis E	33.53	26.17	10	5366	1219	50598529
Arthralgia	30.61	26.17	5	5371	438697	50161051
Stem cell transplant	30.52	26.17	10	5366	1658	50598090
Stenotrophomonas infection	30.51	26.17	10	5366	1659	50598089
Bacterial sepsis	29.71	26.17	12	5364	3600	50596148
Respiratory failure	29.40	26.17	42	5334	91139	50508609
Clostridium bacteraemia	28.16	26.17	6	5370	185	50599563
Colitis	28.08	26.17	27	5349	38502	50561246
Chronic myeloid leukaemia	28.00	26.17	10	5366	2146	50597602
Venoocclusive liver disease	27.80	26.17	12	5364	4249	50595499
Leukopenia	27.72	26.17	35	5341	67493	50532255
Differentiation syndrome	27.23	26.17	8	5368	925	50598823
Cardiomyopathy	26.63	26.17	18	5358	15568	50584180
Aplastic anaemia	26.59	26.17	14	5362	7689	50592059
Streptococcal sepsis	26.33	26.17	9	5367	1698	50598050
Neoplasm progression	26.25	26.17	23	5353	29134	50570614

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile neutropenia	356.91	22.00	253	6468	111987	29455819
Myelodysplastic syndrome	166.27	22.00	81	6640	17713	29550093
Acute myeloid leukaemia	141.85	22.00	71	6650	16442	29551364
Neutropenia	108.39	22.00	141	6580	131570	29436236
Septic shock	100.15	22.00	95	6626	62465	29505341
Bone marrow failure	82.28	22.00	60	6661	27389	29540417
Bronchopulmonary aspergillosis	80.05	22.00	44	6677	12300	29555506
Mucormycosis	75.06	22.00	32	6689	5126	29562680
Fungal infection	73.17	22.00	43	6678	13642	29554164
Second primary malignancy	60.99	22.00	30	6691	6675	29561131
Minimal residual disease	53.61	22.00	13	6708	330	29567476
Bacteraemia	51.89	22.00	37	6684	16286	29551520
Ameloblastoma	51.52	22.00	10	6711	84	29567722
Aspiration bone marrow abnormal	49.50	22.00	10	6711	105	29567701
Leukaemia recurrent	46.18	22.00	16	6705	1461	29566345
Multiple organ dysfunction syndrome	44.75	22.00	63	6658	63053	29504753
Hypertensive hydrocephalus	41.56	22.00	8	6713	64	29567742
Acute lymphocytic leukaemia recurrent	41.26	22.00	17	6704	2499	29565307
Neoplasm progression	39.09	22.00	33	6688	18579	29549227
Haematopoietic neoplasm	37.19	22.00	7	6714	49	29567757
Thrombocytopenia	36.80	22.00	89	6632	134734	29433072
Mucosal inflammation	35.96	22.00	40	6681	31555	29536251
Abscess fungal	35.19	22.00	8	6713	152	29567654
Neoplasm recurrence	34.61	22.00	14	6707	1963	29565843
Cytogenetic abnormality	34.07	22.00	11	6710	808	29566998
Clostridium bacteraemia	33.87	22.00	7	6714	83	29567723
Aspergillus infection	33.66	22.00	24	6697	10557	29557249
Cystitis haemorrhagic	33.43	22.00	18	6703	4824	29562982
Pancytopenia	33.11	22.00	64	6657	83104	29484702
Pneumonia fungal	33.11	22.00	19	6702	5758	29562048
Cardiotoxicity	30.98	22.00	17	6704	4727	29563079
Gallbladder adenocarcinoma	30.02	22.00	5	6716	15	29567791
Product use in unapproved indication	29.98	22.00	63	6658	86812	29480994
Venoocclusive liver disease	29.95	22.00	19	6702	6898	29560908
Sepsis	29.55	22.00	85	6636	142597	29425209
Neutropenic colitis	28.73	22.00	13	6708	2398	29565408
Refractory anaemia with an excess of blasts	27.97	22.00	8	6713	389	29567417
Disease progression	27.80	22.00	59	6662	81857	29485949
Respiratory tract infection fungal	27.73	22.00	9	6712	672	29567134
Klebsiella infection	26.49	22.00	18	6703	7331	29560475
Genotoxicity	26.44	22.00	5	6716	36	29567770
Klebsiella sepsis	26.33	22.00	11	6710	1673	29566133
Enamel anomaly	26.15	22.00	6	6715	119	29567687
Progressive multifocal leukoencephalopathy	25.96	22.00	19	6702	8700	29559106
Colitis	24.85	22.00	33	6688	31215	29536591
Hyperammonaemic encephalopathy	24.57	22.00	11	6710	1979	29565827
Osteonecrosis	24.41	22.00	22	6699	13497	29554309
Fungaemia	23.60	22.00	11	6710	2170	29565636
Differentiation syndrome	23.41	22.00	9	6712	1104	29566702
Large granular lymphocytosis	23.41	22.00	6	6715	192	29567614
Cholangitis infective	22.24	22.00	6	6715	235	29567571

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile neutropenia	537.19	20.30	351	10287	187306	64300788
Acute myeloid leukaemia	328.61	20.30	135	10503	27328	64460766
Myelodysplastic syndrome	314.51	20.30	131	10507	27448	64460646
Neutropenia	179.97	20.30	209	10429	239415	64248679
Second primary malignancy	169.35	20.30	67	10571	12270	64475824
Bone marrow failure	149.43	20.30	95	10543	47857	64440237
Leukaemia recurrent	115.24	20.30	34	10604	2560	64485534
Sepsis	114.60	20.30	164	10474	230177	64257917
Bronchopulmonary aspergillosis	102.75	20.30	54	10584	19031	64469063
Septic shock	101.55	20.30	105	10533	105332	64382762
Thrombocytopenia	99.25	20.30	151	10487	223650	64264444
Pancytopenia	97.41	20.30	119	10519	143190	64344904
Acute promyelocytic leukaemia	92.59	20.30	25	10613	1363	64486731
Mucormycosis	87.39	20.30	36	10602	7305	64480789
Progressive multifocal leukoencephalopathy	77.15	20.30	44	10594	18188	64469906
Acute lymphocytic leukaemia recurrent	73.74	20.30	27	10611	3999	64484095
Fungal infection	71.41	20.30	53	10585	34198	64453896
Product use in unapproved indication	69.65	20.30	113	10525	176505	64311589
Multiple organ dysfunction syndrome	68.50	20.30	84	10554	101329	64386765
Bacteraemia	68.44	20.30	47	10591	26864	64461230
Acute myeloid leukaemia recurrent	63.61	20.30	22	10616	2762	64485332
Venoocclusive liver disease	61.59	20.30	31	10607	9984	64478110
Clostridium bacteraemia	59.92	20.30	13	10625	277	64487817
Haemophagocytic lymphohistiocytosis	55.07	20.30	35	10603	17574	64470520
Aspergillus infection	54.86	20.30	34	10604	16345	64471749
Ameloblastoma	54.71	20.30	10	10628	84	64488010
Neoplasm recurrence	53.72	20.30	21	10617	3718	64484376
Cytogenetic abnormality	52.05	20.30	15	10623	1039	64487055
Refractory anaemia with an excess of blasts	50.67	20.30	14	10624	832	64487262
Lower respiratory tract infection fungal	50.52	20.30	14	10624	841	64487253
Chronic hepatitis	49.31	20.30	15	10623	1253	64486841
Febrile bone marrow aplasia	47.17	20.30	27	10611	11228	64476866
Neoplasm progression	47.15	20.30	45	10593	40919	64447175
Differentiation syndrome	46.03	20.30	16	10622	2038	64486056
Fungaemia	43.15	20.30	18	10620	3767	64484327
Respiratory failure	42.90	20.30	87	10551	161096	64326998
Klebsiella sepsis	42.16	20.30	16	10622	2616	64485478
Drug resistance	41.24	20.30	39	10599	35063	64453031
Stenotrophomonas infection	39.72	20.30	16	10622	3064	64485030
Colitis	38.62	20.30	48	10590	58626	64429468
Stem cell transplant	37.83	20.30	16	10622	3465	64484629
Aplastic anaemia	37.01	20.30	25	10613	13895	64474199
Neutropenic colitis	36.70	20.30	17	10621	4564	64483530
Fatigue	36.51	20.30	42	10596	748688	63739406
Haematotoxicity	36.31	20.30	24	10614	12872	64475222
Abdominal wall wound	36.11	20.30	7	10631	83	64488011
Cystitis haemorrhagic	35.81	20.30	20	10618	7936	64480158
Haematopoietic neoplasm	35.81	20.30	7	10631	87	64488007
Hyperammonaemic encephalopathy	35.47	20.30	16	10622	4042	64484052
Candida infection	35.18	20.30	34	10604	31385	64456709
Malignant neoplasm progression	34.99	20.30	65	10573	112806	64375288
Graft versus host disease	34.81	20.30	24	10614	13789	64474305
Respiratory tract infection fungal	34.42	20.30	11	10627	1081	64487013
Stomatococcal infection	34.16	20.30	8	10630	243	64487851
Myeloblast percentage decreased	33.92	20.30	6	10632	41	64488053
Refractory cytopenia with multilineage dysplasia	33.55	20.30	8	10630	263	64487831
Hypogammaglobulinaemia	33.53	20.30	21	10617	10278	64477816
Cardiomyopathy	33.33	20.30	30	10608	25326	64462768
Bone marrow infiltration	33.28	20.30	9	10629	493	64487601
Hypertensive hydrocephalus	33.06	20.30	5	10633	10	64488084
Enterococcal infection	32.40	20.30	23	10615	13843	64474251
Cardiac failure	32.34	20.30	69	10569	132304	64355790
Pyrexia	31.70	20.30	178	10460	558466	63929628
Mucosal inflammation	31.64	20.30	45	10593	62539	64425555
Nausea	31.33	20.30	51	10587	785749	63702345
Arthralgia	31.33	20.30	17	10621	442243	64045851
Acute lymphocytic leukaemia	31.26	20.30	15	10623	4356	64483738
Hepatic failure	31.25	20.30	42	10596	55352	64432742
Diffuse large B-cell lymphoma recurrent	29.40	20.30	13	10625	3133	64484961
Pain	29.22	20.30	29	10609	553482	63934612
Abscess fungal	28.85	20.30	7	10631	248	64487846
Osteonecrosis	28.73	20.30	29	10609	28200	64459894
Acute febrile neutrophilic dermatosis	28.70	20.30	13	10625	3316	64484778
Pneumonia fungal	28.64	20.30	18	10620	8859	64479235
Drug hypersensitivity	28.57	20.30	3	10635	237812	64250282
Chronic myeloid leukaemia	28.53	20.30	13	10625	3361	64484733
Hepatitis B	28.29	20.30	17	10621	7728	64480366
Fall	28.12	20.30	17	10621	416809	64071285
Chronic lymphocytic leukaemia recurrent	27.70	20.30	8	10630	558	64487536
Lymphopenia	27.29	20.30	27	10611	25630	64462464
Pseudomonas infection	27.21	20.30	23	10615	17860	64470234
Disseminated intravascular coagulation	27.17	20.30	30	10608	32318	64455776
Aspiration bone marrow abnormal	27.09	20.30	6	10632	141	64487953
Disease progression	27.03	20.30	67	10571	141613	64346481
Pruritus	26.91	20.30	9	10629	312391	64175703
Pulmonary haemorrhage	26.67	20.30	20	10618	13089	64475005
Klebsiella infection	26.44	20.30	20	10618	13261	64474833
Cardiotoxicity	26.24	20.30	18	10620	10256	64477838
Leukopenia	26.14	20.30	54	10584	101188	64386906
Chloroma	25.97	20.30	8	10630	697	64487397
Hepatitis E	25.84	20.30	11	10627	2420	64485674
Dizziness	25.75	20.30	20	10618	430143	64057951
Blood culture positive	25.50	20.30	16	10622	7852	64480242
Escherichia bacteraemia	25.46	20.30	14	10624	5389	64482705
Minimal residual disease	25.43	20.30	7	10631	410	64487684
Staphylococcal infection	24.96	20.30	36	10602	50642	64437452
Chromosome analysis abnormal	24.58	20.30	6	10632	218	64487876
Pain in extremity	23.97	20.30	10	10628	303075	64185019
Portal hypertension	23.63	20.30	14	10624	6205	64481889
Streptococcal bacteraemia	23.39	20.30	11	10627	3056	64485038
Pseudomonal sepsis	23.27	20.30	13	10625	5159	64482935
Acute myelomonocytic leukaemia	23.04	20.30	6	10632	284	64487810
Streptococcal sepsis	22.73	20.30	10	10628	2382	64485712
Encephalopathy	22.27	20.30	37	10601	58782	64429312
Nasopharyngitis	22.25	20.30	3	10635	196070	64292024
Cerebral fungal infection	22.11	20.30	6	10632	333	64487761
Metastasis	22.11	20.30	13	10625	5682	64482412
Large granular lymphocytosis	21.94	20.30	6	10632	343	64487751
Leukaemic infiltration	21.70	20.30	5	10633	141	64487953
Chronic myelomonocytic leukaemia	21.33	20.30	7	10631	748	64487346
Bacterial sepsis	21.29	20.30	14	10624	7443	64480651
Pneumonia	21.10	20.30	161	10477	559415	63928679
Acute graft versus host disease	21.06	20.30	15	10623	9069	64479025
Primary hypogonadism	20.75	20.30	5	10633	172	64487922
Parametritis	20.59	20.30	3	10635	4	64488090
Retinal infiltrates	20.51	20.30	4	10634	49	64488045
Cholangitis infective	20.31	20.30	6	10632	453	64487641

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L01DB07	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES Anthracyclines and related substances
FDA MoA	N0000000176	Topoisomerase Inhibitors
MeSH PA	D000700	Analgesics
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D018689	Sensory System Agents
MeSH PA	D059005	Topoisomerase II Inhibitors
FDA EPC	N0000175609	Topoisomerase Inhibitor
CHEBI has role	CHEBI:23240	chromophores
CHEBI has role	CHEBI:37958	dyes
CHEBI has role	CHEBI:76924	plant metabolites
CHEBI has role	CHEBI:35610	antineoplastic agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Acute myeloid leukemia, disease	indication	91861009
Relapsing remitting multiple sclerosis	indication	426373005	DOID:2378
Metastatic Prostate Carcinoma	indication
Follicular non-Hodgkin's lymphoma	off-label use	308121000
Metastatic Breast Carcinoma	off-label use
Progressive Diffuse Large B-Cell Lymphoma	off-label use
Mycosis	contraindication	3218000	DOID:1564
Viral disease	contraindication	34014006	DOID:934
Chronic heart failure	contraindication	48447003
Hepatic failure	contraindication	59927004
Acute infectious disease	contraindication	63171007
Leukopenia	contraindication	84828003	DOID:615
Left heart failure	contraindication	85232009
Bacterial infectious disease	contraindication	87628006
Radiation oncology AND/OR radiotherapy	contraindication	108290001
Acute disease of cardiovascular system	contraindication	128487001
Seizure disorder	contraindication	128613002
Disease of liver	contraindication	235856003	DOID:409
Anemia	contraindication	271737000	DOID:2355
Pregnancy, function	contraindication	289908002
Thrombocytopenic disorder	contraindication	302215000	DOID:1588
Neutropenic disorder	contraindication	303011007	DOID:1227
Bone marrow depression	contraindication	307762000
Breastfeeding (mother)	contraindication	413712001

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.37	acidic
pKa2	10.7	acidic
pKa3	9.13	Basic
pKa4	8.52	Basic
pKa5	4.01	Basic
pKa6	1.49	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
DNA topoisomerase 2-alpha	Enzyme	P11388	TOP2A_HUMAN	INHIBITOR	IC90	5.96	WOMBAT-PK	CHEMBL
Multidrug resistance protein 1	Transporter	P08183	MDR1_HUMAN		IC50	5.84	WOMBAT-PK
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		Ki	5.31	DRUG MATRIX
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN		Ki	5.73	DRUG MATRIX
Muscarinic acetylcholine receptor M1	GPCR	P11229	ACM1_HUMAN		Ki	6.74	DRUG MATRIX
Muscarinic acetylcholine receptor M2	GPCR	P08172	ACM2_HUMAN		Ki	7.11	DRUG MATRIX
Muscarinic acetylcholine receptor M4	GPCR	P08173	ACM4_HUMAN		Ki	7.05	DRUG MATRIX
Canalicular multispecific organic anion transporter 1	Transporter	Q92887	MRP2_HUMAN				WOMBAT-PK
Multidrug resistance-associated protein 1	Transporter	P33527	MRP1_HUMAN		IC50	6.29	WOMBAT-PK
ATP-binding cassette sub-family G member 2	Transporter	Q9UNQ0	ABCG2_HUMAN		Kact	5.16	WOMBAT-PK
Epidermal growth factor receptor	Kinase	P00533	EGFR_HUMAN		IC50	5.27	DRUG MATRIX
Tyrosine-protein kinase Fyn	Kinase	P06241	FYN_HUMAN		IC50	5.90	DRUG MATRIX
Receptor tyrosine-protein kinase erbB-2	Kinase	P04626	ERBB2_HUMAN		IC50	5.69	DRUG MATRIX
Serine/threonine-protein kinase pim-1	Kinase	P11309	PIM1_HUMAN		IC50	7.29	CHEMBL
Solute carrier family 22 member 1	Transporter	O15245	S22A1_HUMAN		IC50	4.36	CHEMBL
DNA-(apurinic or apyrimidinic site) lyase	Enzyme	P27695	APEX1_HUMAN		IC50	5.70	CHEMBL
Tyrosine-protein kinase BTK	Kinase	Q06187	BTK_HUMAN		IC50	6	CHEMBL
Proto-oncogene tyrosine-protein kinase ROS	Kinase	P08922	ROS1_HUMAN		IC50	5.52	CHEMBL
Solute carrier family 22 member 2	Transporter	O15244	S22A2_HUMAN		IC50	4.13	CHEMBL
Multidrug and toxin extrusion protein 1	Transporter	Q96FL8	S47A1_HUMAN		IC50	6.72	CHEMBL
Multidrug and toxin extrusion protein 2	Transporter	Q86VL8	S47A2_HUMAN		IC50	6.28	CHEMBL
Solute carrier family 22 member 3	Transporter	O75751	S22A3_HUMAN		IC50	4.22	CHEMBL
DNA-3-methyladenine glycosylase	Enzyme	P29372	3MG_HUMAN		IC50	5.60	CHEMBL
Potassium voltage-gated channel subfamily H member 2	Ion channel	Q12809	KCNH2_HUMAN		Ki	5.53	DRUG MATRIX
TAR DNA-binding protein 43	Unclassified	Q13148	TADBP_HUMAN		IC50	5	CHEMBL
Arachidonate 15-lipoxygenase	Enzyme		LOX15_RABIT		IC50	5.75	DRUG MATRIX
Integrase	Enzyme		Q7ZJM1_9HIV1		IC50	5.42	CHEMBL
Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Kinase		DYR1A_RAT		AC50	5.02	CHEMBL

External reference:

ID	Source
4019842	VUID
N0000147929	NUI
D02166	KEGG_DRUG
70476-82-3	SECONDARY_CAS_RN
4019527	VANDF
4019842	VANDF
C0026259	UMLSCUI
CHEBI:50729	CHEBI
MIX	PDB_CHEM_ID
CHEMBL58	ChEMBL_ID
CHEMBL1417019	ChEMBL_ID
CHEMBL1200827	ChEMBL_ID
D008942	MESH_DESCRIPTOR_UI
DB01204	DRUGBANK_ID
7242	IUPHAR_LIGAND_ID
4922	INN_ID
BZ114NVM5P	UNII
4212	PUBCHEM_CID
203129	RXNORM
5124	MMSL
81184	MMSL
d00306	MMSL
002676	NDDF
004828	NDDF
108791001	SNOMEDCT_US
386913001	SNOMEDCT_US
412249002	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
mitoXANTRONE	HUMAN PRESCRIPTION DRUG LABEL	1	0703-4680	INJECTION, SOLUTION, CONCENTRATE	2 mg	INTRAVENOUS	ANDA	24 sections
mitoXANTRONE	HUMAN PRESCRIPTION DRUG LABEL	1	0703-4685	INJECTION, SOLUTION, CONCENTRATE	2 mg	INTRAVENOUS	ANDA	24 sections
mitoXANTRONE	HUMAN PRESCRIPTION DRUG LABEL	1	0703-4686	INJECTION, SOLUTION, CONCENTRATE	2 mg	INTRAVENOUS	ANDA	24 sections
Mitoxantrone	HUMAN PRESCRIPTION DRUG LABEL	1	61703-343	INJECTION, SOLUTION, CONCENTRATE	2 mg	INTRAVENOUS	ANDA	28 sections
Mitoxantrone	HUMAN PRESCRIPTION DRUG LABEL	1	61703-343	INJECTION, SOLUTION, CONCENTRATE	2 mg	INTRAVENOUS	ANDA	28 sections
Mitoxantrone	HUMAN PRESCRIPTION DRUG LABEL	1	63323-132	INJECTION, SOLUTION	2 mg	INTRAVENOUS	ANDA	15 sections